Oue et al. have suggested that it could be pertinent to conduct WT1 mutation analysis with bilateral Wilms tumors, as mutations in WT1 have also been implicated in renal pathologies that may eventually lead to ESRF [93,95]. The gene discussed is WT1; the disease is Wilms tumor.